Article Per Year (5 Year)
p-Index From 2021 - 2026
2.765
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmaceutical Science and Technology Jurnal Farmasi Klinik Indonesia INDONESIAN JOURNAL OF PHARMACY JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Jurnal Penelitian Pendidikan IPA (JPPIPA) Jurnal Pengabdian Pada Masyarakat Window of Health : Jurnal Kesehatan JFIOnline JURNAL MEDIA KESEHATAN Majalah Farmasetika Indian Journal of Forensic Medicine & Toxicology Folia Medica Indonesiana Journal of Pharmascience
Budi Suprapti
Departemen Farmasi Praktis, Fakultas Farmasi Universitas Airlangga Surabaya, Indonesia
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Decision Sciences, Operations Research & Management Education Engineering Health Professions Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Other

Published : 32 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 32 Documents
Search

 1   2   3   4 
The Potential of Probiotic Role in Tuberculosis Therapy : A Narrative Review Fitriani, Victoria yulita; Suprapti, Budi; Amin, Muhammad
Indonesian Journal of Pharmaceutical Science and Technology 2024: Suppl. 6, No. 1 (Special Issue for Mulawarman Pharmaceutical Conference)
Publisher : Indonesian Journal of Pharmaceutical Science and Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/ijpst.v6i1.53635

Abstract

Tuberculosis is an infectious disease that is a leading cause of death globally, as well as one of the top ten causes of death from a single infectious agent. Antibiotics treatment for tuberculosis reduces pro-inflammatory cytokines, which is one of the reasons for dysbiosis. The proportion of Actinobacteria, Firmicutes, and Bacteroidetes in the gut microbiota distinguishes between drug-sensitive and drug-resistant tuberculosis. The gut–lung axis theory explains how tuberculosis alters the gut microbiota while also altering the immune response. Probiotics have immunostimulatory and immunoregulatory properties that affect the immune system. The gut-lung axis is a two-way system that enables microbial products, endotoxins, metabolites, hormones, and cytokines to reach the bloodstream that connects the intestines and lungs, where they exert effects on both. According to the gut–lung axis theory, probiotics may play a role in tuberculosis immune responses. This review includes studies conducted in English and Indonesian from 2010-2022. The Cochrane Library, Scopus, Medline, PubMed, and grey literature databases will be used in the review. Studies that use specimens from pulmonary tuberculosis patients, healthy volunteers induced by Mycobacterium tuberculosis, volunteers with a history of pulmonary tuberculosis disease, and volunteers who had close contact with pulmonary tuberculosis patients were considered eligible. The current review highlights the immune modulation induced by probiotics usage in tuberculosis. Accordingly, probiotics have been shown to enhance the immune response against tuberculosis. More studies are needed to understand probiotic’s role in different types of tuberculosis, and the influence of different probiotic bacteria on immune modulation.
Use of Medication in Outpatient Hypertension Patients Bulqiah, Andi; Suprapti, Budi; Ardiana, Shafira muti; Alsagaff, M. Yusuf; Suharjono
Window of Health : Jurnal Kesehatan VoL 6 No 2 (April 2023)
Publisher : Fakultas Kesehatan Masyarakat Universitas Muslim Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (623.497 KB) | DOI: 10.33096/woh.vi.66

Abstract

Hypertension is a major risk factor for cardiovascular disease, there are 1.13 billion people in the world suffering from hypertension. Hypertension should be given special consideration due to its impact on both the short and long term, one of which is by providing appropriate pharmacological therapy. The purpose of this study is to ascertain the pattern of medication use in hypertensive patients. The current study is a retrospective observational study that examines drug use patterns in hypertensive patients with or without associated disease. Using time-limited sampling techniques, the study sample is drawn from an electronic prescription of outpatient hypertension patients at Universitas Airlangga Surabaya Hospital (RSUA) in March 2021. According to the findings of this study, the most frequently prescribed antihypertensive medications were beta-blockers (29,66 %), ARB (27,51 %), CCB (26,17 %), aldosterone antagonists (6,72 %), loop diuretics (5,78 %), ACEi (3,98 %), and central α2 agonists (3,98 %) (0,14 % ). Antihypertension medications are prescribed singly or in combination. In hypertensive patients with co-morbidities, drugs other than antihypertensives will be prescribed to treat the co-morbidities. The most frequently prescribed non-antihypertensive drugs are antihyperlipidemia statin (45,1 %), platelet antiagregation (19,1%), and antiangina (13,8 %). The study concludes that antihypertension medications are used alone or in combination with up to five other antihypertensive medications, with the most common combination being three drugs in 45% of patients. Suggestions for this study are that it should be accompanied by direct patient identification to minimize the incidence of drug interactions and drug side effects in patients.
Effect of hydroxyethyl starch 200/0.5 on von willebrand factor serum level and activated partial thromboplastin time (aptt) Atmaja, Sarah Puspita; Khotib, Junaidi; Rahardjo, Eddy; Shinta, Dewi Wara; Rahmadi, Mahardian; Suprapti, Budi
Folia Medica Indonesiana Vol. 51, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hydroxyethyl starch (HES) is a colloid administered frequently for intravascular volume expansion during perioperative period. Impairment of haemostasis have been reported during HES administration, but the volume of solution administered was usually higher than 20 ml.kg-1. The objective of this study was to evaluate the effect of Hydroxyethyl starch 200/0.5 dose less than 20 ml.kg-1 on von Willebrand factor serum level and activated partial thromboplastin time. A prospective, observational study was conducted to evaluate von Willebrand factor and activated partial thromboplastin time of patients receiving Hydroxyethyl starch 200/0.5. Inclusion criteria were patients undergoing elective surgery who were going to receive Hydroxyethyl starch 200/0.5 intraoperatively. Fourty six patients were divided into patients receiving crystalloid only group (n=23 patients) and hydroxyethyl starch (n=23 patients). Coagulation variables were assesed 30 minute after insicion and 60 minute after infusion of crystalloid or colloid. Measurement of von Willebrand within each group after crystalloid or HES 200 infusion showed significant decrease, from (mean±SE) 97.688±15.219 ng/ml to 31.611±10.058 ng/ml (p< 0.001) in crystalloid group and 92.884±15.208 ng/ml to 27.378±6.399 ng/ml (p<0.001) in HES 200 group. Activated partial thromboplastin time change was statistically significant (mean±SE) 31.27±1.39 to 35.61±1.62 in HES group only (p=0.007), but this change was not clinically significant. In conclusion, there was neither significant difference in von Willebrand serum level nor in activated partial thromboplastin time between the two groups. There was no coagulation influence with clinically significant effect in the use of HES 20 ml/kg BW in patients undergoing elective surgery.
Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis Purwiningtyas, Mida; Yulistiani, Yulistiani; Suprapti, Budi; Santi, Bayu Dharma
Folia Medica Indonesiana Vol. 55, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Every year, there are 500.000 new cases and more than 250.000 deaths caused by cervical cancerworldwide. Cervical cancer patients faced physical and psychological problems several times that it activate stress mechanism such as hypothalamus-pituitary-adrenal (HPA) axis. These recurrent activations caused HPA axis disruption and adverse clinical effects. Several symptoms of endocrine stress response are the change of circadian cortisol rhythm. Cortisol is known as a stress hormone that involves an organism's response to stress and anxiety that influence the quality of life. This research aims to analyze the differences among serum cortisol level, anxiety, and quality of life in cervical cancer patients before and after psychocurative intervention in obstetrics and gynecology wards and polyclinic in RSUD Dr. Moewardi Surakarta. This research is an experimental double-blind randomized controlled clinical trial pre-test post-test group design study. The subjects were advance stage (IIB-IV)cervical cancer patients. The subjects were randomly chosen into fifteen subjects that given standard therapy and psychocurative, while the other fifteen subjects as a control only got standard therapy. Data were obtained from measurement of serum cortisol level, anxiety questionnaire DASS 42 and WHO quality of life questionnaire. Data were analyzed using SPSS 21 using difference test. The difference mean test result of cortisol serum level, anxiety, quality of life from the controlled group and uncontrolled group showed a significant difference (p < 0.05). In conclusion, psychocurative is significant to reduce cortisol level, anxiety, and improve the quality of life in advanced stage cervical cancer patients.
Effectivity of Erythropoietin Alpha Compared to Erythropoietin Beta in Patients with Chronic Kidney Disease-Anemia on Hemodialysis Prasetya, Anak Agung Ngurah Putra Riana; Suprapti, Budi; Shanti, Bayu Dharma
Folia Medica Indonesiana Vol. 55, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Anemia in patient with chronic kidney disease could cause a lot of complication. The first line therapy of this condition is by treating with erythropoiesis-stimulating agents (ESA) or called erythropoietin. The erythropoietin alpha and beta were two types of the human recombinant erythropoietin that are usually used in Indonesia. The aim of this study was to determine the effectivity of erythropoietin alpha compared to erythropoietin beta especially in haemoglobin and haematocrit level. This prospective observational study was conducted in March – September 2016. The inclusion criteria were CKD stage 5 patients with a minimum of 3 months of regular hemodialysis, Hb <10 g/dL with enough iron status ST > 20% and FS > 200ng/mL. The methology of this study had been approved by the Health Research Ethics Committee of the Bhayangkara H.S. Samsoeri Mertojoso Hospital, Surabaya. Patients received 2000 IU subcutaneous erythropoietin twice a week on both groups. Blood sample was withdrawn in pre-treatment and after 4 weeks of post erythropoietin therapy treatment for measurement of haemoglobin and haematocrit. Target for this erythropoietin therapy are increase of Hb 0.5 – 1.5 g/dL (not to exceed 12 g/dL) and increase of Hct level 2 – 4 % in 4 weeks. Based on the inclusion criteria, there were 20 patients in this study (10 patient each of both erythropoietin alpha either beta group) that consist of 7 women and 13 men. After the treatment, the mean of increased haemoglobin level for erythropoietin alpha group was 1.28 ± 0.80 g/dL (p=0.001) and erythropoietin beta was 0.37 ± 0.95 g/dL (p=0.254). The mean of increased haematocrit level for erytropoietin alpha group was 3.56 ± 3.46 % (p=0.010) and erythropoietin beta was 1.34 ± 2.71 % (p=0.152). In comparison of haemoglobin and haematocrit achievement in both groups showed that erythropoietin alpha gave better achievement in haemoglobin parameter (p=0.033), but there were no differences in both groups on haematocrit parameters (p=0.127).
The use of hydroxyethyl starch 200/0,5 as plasma subtitutes is safe in hypovolemic patients as indicated in changes of n-acetyl--glucosaminidase and creatinin serum parameters Shinta, Dewi Wara; Khotib, Junaidi; Rahardjo, Eddy; Rahmadi, Mahardian; Suprapti, Budi
Folia Medica Indonesiana Vol. 51, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hydroxyethyl Starch (HES) is a compound that improves intravascular volume effectively and rapidly without causing tissue edema. However, HES also has renal safety profile which is still being debated. Based on clinical experience in Dr. Soetomo Hospital, the frequency of acute renal failure following HES 200/0.5 administration at a dose of less than 20 ml/kg (maximum dose) is very rare. The purpose of this study was to evaluate the effect of HES 200/0.5 at a dose of less than 20 ml/kg in patients undergoing surgery. N-acetyl-b-D-Glucosaminidase (NAG) per urine creatinine ratio and creatinine serum were used as main parameter to assess renal injury. This research was observational and prospective design in patients undergoing elective surgery at Gedung Bedah Pusat Terpadu, Dr. Soetomo Hospital, who requiring resuscitation therapy with HES 200/0.5 and met the inclusion and exclusion criteria. NAG was measured prior to surgery and 12 hours after administration of fluid therapy, while creatinine serum was observed before surgery and 48 hours after resuscitation. This study was conducted for three months, and obtained 50 subjects divided into 2 groups, crystalloid group and HES 200/0.5 group. Demographic and baseline characteristics did not differ between groups, except the total bleeding volume. Total bleeding in HES 200/0.5group was higher than crystalloid group (p <0.0001). The mean volume of fluid received in HES 200/0.5 group was 2042.0 ± 673.9 mL, higher when compared with that of crystalloid group (910.0 ± 592.0 ml). Doses of HES 200/0.5 received was 8.31 ± 4.86 ml/kg. Measurement of the of NAG/creatinine ratio and creatinine serum showed significant increase in both groups, but still within the normal range. In addition, the value of these two parameters did not differ between groups. In conclusion, HES 200/0.5 in a dose of less than 20 ml/kg is safe to use in patients who suffered from hypovolemic hemorrhage, without prior history of renal impairment.
Comparison of the antiemetic effectiveness between granisetron and dexamethasone with ondansetron and dexamethasone in acute-phase chemotherapy patients Arfiani, Ria Fitrah; Susilo, Dwi Hari; Suprapti, Budi
Folia Medica Indonesiana Vol. 52, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Nausea and vomiting may occur in patients receiving chemotherapy, a condition referred to as chemotherapy-induced nausea and vomiting. The provision of combined dexamethasone and ondansetron or granisetron is the therapeutic management of acute phase nausea and vomiting in cytostatics with a high risk of nausea and vomiting. Granisetron has been known to have better pharmacokinetics and pharmacodynamics compared to ondansetron, so it is possible to have nausea and vomiting suppressing effect higher than that of ondansetron. This study aimed to compare antiemetic effectiveness of granisetron and dexamethasone with ondansetron and dexamethasone in acute-phase chemotherapy patients. This study was conducted in patients who received the combination of cisplatin-paclitaxel and cisplatin-fluorouracil, double-blind, with samples comprised new head and neck surgical oncology patients. Measurement of nausea and vomiting during the acute phase of chemotherapy was conducted using Index of Nausea, Vomiting, and Retching (INVR). Observation of nausea and vomiting in the patients was done during the first 12 hours after administration of cisplatin and interviews were conducted on h 12. Results showed that there was no difference in the effectiveness of nausea and vomiting suppression in the administration of granisetron and dexamethasone compared to ondanstron and dexamethasone in acute phase chemotherapy patients (p = 0.076).
Kajian Literatur : Tinjauan Terapi Kardioprotektan untuk Penanganan Kardiotoksisitas Kemoterapi Antrasiklin Cinantya Meyta Sari; Budi Suprapti; Nurmainah Nurmainah
Journal of Pharmascience Vol. 12 No. 1 (2025): Jurnal Pharmascience
Publisher : Universitas Lambung Mangkurat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20527/jps.v12i1.19910

Abstract

Saat ini telah banyak diteliti mengenai beberapa agen farmakologi untuk terapi penanganan kardiotoksisitas antrasiklin. Namun, dibutuhkan kajian lebih lanjut terhadap strategi terapi kardiotoksisitas antrasiklin tersebut dari segi kefarmasian untuk memperkaya referensi sebagai dasar praktek klinis untuk tatalaksana kardiotoksisitas, terutama di negara berkembang. Kajian literatur ini bertujuan mengkaji lebih mendalam terkait kardioprotektan dari aspek mekanisme kerja, karakteristik farmakokinetik, serta dari evidence based medicine yang ada. Kajian literatur secara komprehensif dilakukan berdasarkan penelusuran jurnal ilmiah melalui penelusuran elektronik dengan kata kunci kombinasi “cardioprotective”, “anthracycline”, dan “cardiotoxicity”. Dari seluruh artikel yang diperoleh, didapatkan 39 artikel yang dapat dikaji lebih lanjut, yakni artikel mengenai kardiotoksisitas antrasiklin, serta penelitian dan bukti ilmiah mengenai agen-agen farmakologi yang diteliti bersifat kardioprotektif. Kesimpulan dari tinjauan ini adalah beberapa agen farmakologis telah menunjukkan luaran yang baik pada beberapa parameter kardiotoksisitas, namun penelitian tingkat lanjut dengan skala lebih besar dan waktu  follow up yang lebih lama masih diperlukan terutama dengan sampel domestik agar dapat diperoleh konklusi yang dapat diaplikasikan secara klinis pada masyarakat Indonesia.
Scientific Analysis with a Retrospective Method on the Incidence and Severity of Adverse Drug Reactions in Hospitalized Cancer Patients Diyah Wahyuni; Cinantya Meyta Sari; Budi Suprapti
Jurnal Penelitian Pendidikan IPA Vol 10 No 9 (2024): September
Publisher : Postgraduate, University of Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/jppipa.v10i9.8624

Abstract

Adverse Drug Reactions (ADRs) often result from omissions or inadequate use of preventative measures, making them definitely or probably preventable. Discrepancies between clinical severity and patients' perceptions of ADRs' impact on their well-being highlight the need for targeted interventions. This study focused on the frequency, manifestations, and severity of ADRs from chemotherapeutic agents, utilizing a cross-sectional design with data from ADR reports spanning November 2021 to October 2023 at dr. Saiful Anwar General Hospital, Indonesia. A total of 177 ADRs were analyzed descriptively. Of these, 99 (55.93%) occurred in women, with the highest incidence in the 19–60-year age group (77.40%). The most common malignancies were Chronic Myeloid Leukemia (10.17%), Colorectal Malignancy, and Non-Hodgkin Lymphoma (9.60% each). ADRs related to chemotherapy constituted 41.80%, involving drugs such as cisplatin, oxaliplatin, afatinib, imatinib, and Doxorubicin. The severity distribution was 70.37% mild, 27.16% moderate, and 2.47% severe. Monitoring and reporting these ADRs are crucial for patient safety and preventing recurrence.
Adverse Drug Reactions Reporting Profile in Tertiary Referral Hospital: A Retrospective Pharmacovigilance Study in Indonesia Cinantya Meyta Sari; Budi Suprapti
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 11 No. 2 (2024): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v11i22024.174-183

Abstract

Background: Pharmacovigilance is administered to several pharmacological classes of drugs worldwide. However, there are still insufficient data regarding the prevalence and general characteristics of drug reactions, especially in developing countries. Objective:  This study aimed to determine the prevalence and characteristics of ADRs, including the pharmacological class involved, and report and classify the clinical manifestations associated with ADRs. Methods: This retrospective study was based on patient ADR reports during observation. Prevalence, patient demographics, and other data were evaluated using descriptive statistics. Results: Of 773 reports that met the inclusion criteria, most were doctors (80.6%), followed by pharmacists (18.7%). Of the total cases, 430 (55.6%) occurred in the women. Most suspected ADRs occurred in the 19-60 years age group (583; 75.4%). The highest incidence of ADR was observed in patients using antineoplastic agents (19.5%), systemic antibacterials (16.4%), or antihypertensives (12.5%). The majority of clinical manifestations were gastrointestinal disorders (41.7%), and approximately 309 (40%) ADR cases continued with antagonists/antidotes. Approximately 62% of the patients who experienced ADRs recovered. Conclusion: Antineoplastic, systemic antibacterial, and antihypertensive drugs appeared to be the most common drugs used for suspected ADR cases in this hospital. ADR reporting has been running well, but not all healthcare workers have participated actively. Hopefully, the results of this research will contribute to the upcoming strategies for pharmacovigilance activities in this hospital and other healthcare facilities to improve the quality and quantity of ADR reporting and increase the safety of medication usage.
Co-Authors Abdul Rahman Bahmid Aditiawardana Aditiawardana, Aditiawardana Alsagaff, M. Yusuf Andarsari, Mareta R. Aniek S. Budiatin Ardiana, Shafira muti Arfiani, Ria Fitrah Arief Bachtiar Arina Deri Puspita Sari Arina Dery Puspitasari Ayunda Nur Hidayatiningsih Azril O. Ardhiansyah Bambang Subakti Zulkarnain Bella Donna Perdana Putra Budiatin, Aniek S. Bulqiah, Andi Cahyo Wibisono Cahyo Wibisono Nugroho Chrysnanda Maryska Cinantya Meyta Sari Cinantya Meyta Sari Cinantya Meyta Sari Dewi Damayanti Dewi Makmuroh Nurul Qomar Purnamawati Dewi W. Shinta Dewi Wahyuni Dewi Wara Shinta Didik Hasmono Dinda Monika Nusantara Ratri Dinda Monika Nusantara Ratri Diyah Wahyuni Eddy Rahardjo Fathia Ramadiani Fatimatuz Zahra Oviary Satryo FITRIANI, VICTORIA YULITA Hapsari, Pharmasinta P. Hartono, Frenky Hidayati, Movita I Gde Raka Widiana Idha, Arofa Idha, Arofa Junaidi Khotib Khusnul Fitri Hamidah Kusmiati, Tutik M. Yusuf M. Yusuf Assegaf Mahardian Rahmadi Mansur, Mifta Marcha Debby Saraswati Marcha Debby Saraswati Marcha Debby Saraswati Mareta R. Andarsari Mareta Rindang Andarsari Mochamad Yusuf Alsagaff Muhammad Amin Mulya Sundari Ni Made Amelia R. Dewi Ni Made Mertaniasih Nia Widyasari Novan Y. I. Pratama Nurmainah Nurmainah Nurmainah Nurmainah Pharmasinta P. Hapsari Pharmasinta Putri Hapsari Prasetya, Anak Agung Ngurah Putra Riana Prastuti Asta Wulaningrum Purwiningtyas, Mida Putranto, J.Nugroho Eko Rahmawati Raising Ramadiani, Fathia Retna Dwi Puspitarini S. Soedarsono Santi, Bayu Dharma Santoso, Agustinus Santoso, Agustinus Sarah Puspita Atmaja Sari, Cinantya Meyta Selvia Febriana Astuti Sensusiati, Anggraini Dwi Shafira Muti Ardiana Shanti, Bayu Dharma Shanti, Bayu Dharma Shinta, Dewi W. Sjamsiah, Siti Sjamsiah, Siti Sofiati Diah Baisuni Suharjono Suharjono Susilo, Dwi Hari Thomas Erwin Christian Junus Huwae Toetik Aryani UMI FATMAWATI Wenny Putri Nilamsari WENNY PUTRI NILAMSARI, WENNY PUTRI Yosiyanita Safari Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Zamrotul Izzah Zedny Norachuriya Zuhri, Muhammad Isnaini